Cargando…

Apelin/APJ system: A key therapeutic target for liver disease

Apelin, a new bioactive peptide, was identified as an endogenous ligand for APJ (Angiotensin II receptor-like 1). Apelin and its receptor have an abundant distribution in central nervous system and peripheral tissues, including liver. Apelin/APJ has diverse physiological and pathological effects, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Shuang-Yu, Cui, Binbin, Chen, Wei-Dong, Wang, Yan-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762386/
https://www.ncbi.nlm.nih.gov/pubmed/29340118
http://dx.doi.org/10.18632/oncotarget.22841
_version_ 1783291677891362816
author Lv, Shuang-Yu
Cui, Binbin
Chen, Wei-Dong
Wang, Yan-Dong
author_facet Lv, Shuang-Yu
Cui, Binbin
Chen, Wei-Dong
Wang, Yan-Dong
author_sort Lv, Shuang-Yu
collection PubMed
description Apelin, a new bioactive peptide, was identified as an endogenous ligand for APJ (Angiotensin II receptor-like 1). Apelin and its receptor have an abundant distribution in central nervous system and peripheral tissues, including liver. Apelin/APJ has diverse physiological and pathological effects, including regulation of cardiovascular function, angiogenesis, fluid homeostasis and so on. Apelin/APJ system may act as a novel potential therapeutic target for liver disease. In this article, we review the role of apelin/APJ system in liver fibrosis, hepatitis, hepatic cirrhosis, liver injury and metabolic liver disease.
format Online
Article
Text
id pubmed-5762386
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-57623862018-01-16 Apelin/APJ system: A key therapeutic target for liver disease Lv, Shuang-Yu Cui, Binbin Chen, Wei-Dong Wang, Yan-Dong Oncotarget Review Apelin, a new bioactive peptide, was identified as an endogenous ligand for APJ (Angiotensin II receptor-like 1). Apelin and its receptor have an abundant distribution in central nervous system and peripheral tissues, including liver. Apelin/APJ has diverse physiological and pathological effects, including regulation of cardiovascular function, angiogenesis, fluid homeostasis and so on. Apelin/APJ system may act as a novel potential therapeutic target for liver disease. In this article, we review the role of apelin/APJ system in liver fibrosis, hepatitis, hepatic cirrhosis, liver injury and metabolic liver disease. Impact Journals LLC 2017-12-01 /pmc/articles/PMC5762386/ /pubmed/29340118 http://dx.doi.org/10.18632/oncotarget.22841 Text en Copyright: © 2017 Lv et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Lv, Shuang-Yu
Cui, Binbin
Chen, Wei-Dong
Wang, Yan-Dong
Apelin/APJ system: A key therapeutic target for liver disease
title Apelin/APJ system: A key therapeutic target for liver disease
title_full Apelin/APJ system: A key therapeutic target for liver disease
title_fullStr Apelin/APJ system: A key therapeutic target for liver disease
title_full_unstemmed Apelin/APJ system: A key therapeutic target for liver disease
title_short Apelin/APJ system: A key therapeutic target for liver disease
title_sort apelin/apj system: a key therapeutic target for liver disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762386/
https://www.ncbi.nlm.nih.gov/pubmed/29340118
http://dx.doi.org/10.18632/oncotarget.22841
work_keys_str_mv AT lvshuangyu apelinapjsystemakeytherapeutictargetforliverdisease
AT cuibinbin apelinapjsystemakeytherapeutictargetforliverdisease
AT chenweidong apelinapjsystemakeytherapeutictargetforliverdisease
AT wangyandong apelinapjsystemakeytherapeutictargetforliverdisease